# Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

> **NCT05860296** · PHASE1,PHASE2 · TERMINATED · sponsor: **SignalChem Lifesciences Corporation** · enrollment: 36 (actual)

## Conditions studied

- Lung Cancer, Nonsmall Cell
- Lung Cancer Stage IV
- Lung Cancer Metastatic

## Interventions

- **DRUG:** SLC-391
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT05860296
- **Lead sponsor:** SignalChem Lifesciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-31
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Lack of efficacy and enrollment challenges
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05860296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05860296, "Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05860296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*